Latest news with #IGI
Globe and Mail
15-07-2025
- Business
- Globe and Mail
Ouros Jewels Expand Its Reach as Demand for Ethical Diamond Jewelry Grows
Ouros Jewels Expand Its Reach as Demand for Ethical Diamond Jewelry Grows The demand for ethical diamond jewelry is still rising as more people search for environmentally friendly and ethical options. Certified lab-grown diamonds are currently regarded as a lovely and environmentally friendly substitute for mined gems. One brand is emerging as a prominent name in contemporary fine jewelry thanks to a great emphasis on transparency, quality, and environmentally aware methods. Ouros Jewels is helping to create a more deliberate and environmentally friendly future for the sector, hence contributing to this transition. The Rise of Ethical Jewelry: How Brands Are Redefining Luxury. Ouros Jewels perfectly embodies the ethical luxury of tomorrow. Designed with accuracy, grace, and ecological responsibility, the brand has a broad selection of lab-grown diamond jewelry, including tennis bracelets, engagement rings, eternity bands, and bespoke creations. What makes Ouros Jewels stand out? Certified Lab-Grown Diamonds: Every piece features IGI- or GIA-certified diamonds grown using cutting-edge HPHT or CVD technology. Conflict-Free Promise: Ouros Jewels uses only lab-grown diamonds that are certified and ethically created in controlled environments. This means no mining, no harm to people or the planet, and absolutely no connection to conflict zones or forced labor. Sustainable Production: Ouros Jewels carefully crafts each piece using recycled gold and planet-friendly packaging, while following carbon-neutral practices to minimize environmental harm. Transparent Manufacturing: Customers are educated about the full journey of their jewelry. These values are not just marketing buzzwords, they're embedded in every aspect of the company's operations. Sustainability in Style – The Ouros Jewels Difference Ouros Jewels creates jewelry that is beautiful, ethical, and of great quality by fusing contemporary design with ethical principles. Ouros, a rising eco-friendly jewelry brand, sells items that capture personal flair as well as concern for the earth. The brand is committed to using only lab-grown diamonds, therefore avoiding mining and greatly reducing environmental impact. Each stone is created using ethical processes and can be totally tracked from origin to finish, hence advancing trust and openness. Trusted laboratories such as IGI and GIA certify all diamonds, therefore providing customers with confidence. Through online channels, Ouros makes it simple for consumers to obtain sustainable luxury and ethical fine jewelry by means of worldwide delivery. Ouros is assisting in creating the future of contemporary jewelry by concentrating on ethically sourced, lab-grown diamond rings and exquisite design. It shows that genuine harmony is possible between style, quality, and sustainability. Expanding Reach – How Ouros Is Growing Globally Ouros Jewels online store and virtual consultation services make sustainable luxury more accessible to consumers. Offering a customized shopping experience, the brand also has locations in New York, London, Dubai, and Osaka City. The brand is still growing by entering prominent markets, partnering with artists, and starting worldwide marketing initiatives. These initiatives enable more people to find and relate to Ouros and its ethical jewelry lines. Ouros currently delivers to many places throughout many areas thanks to quick delivery, dependable service, and a physical presence in major cities. More consumers are picking reliable choices like lab-grown diamond rings, ethical diamond patterns, and certified fine jewelry. Ouros Jewels keeps its attention on providing exquisite, environmentally friendly products to consumers all across as demand increases. The Future of Ethical Jewelry with Ouros Ouros Jewels is preparing for the future with fresh ideas that focus on both style and sustainability. The brand is working on new collections that reflect modern tastes while staying true to its ethical values. Its long-term goal is to lead the change in the jewelry industry by offering beautiful pieces that are responsibly made. Ouros aims to expand its product range, improve delivery services, and maintain clear and honest practices in everything it does. As more people choose mindful shopping and cleaner production, Ouros continues to focus on what truly matters: quality, trust and responsible design. Choose Jewelry That Shines with Purpose Ouros Jewels is becoming a trusted name for stylish and ethical jewelry. We offer lab-grown diamond rings and a full range of eco-friendly fine jewelry that's better for you and the planet. You can even design your piece with help from our experts. Visit our Ouros Jewels to shop lab-grown diamond jewelry online and follow us on social media for the latest styles. Choose jewelry that looks great and feels right and join the movement toward a more responsible future.
Mint
14-07-2025
- Business
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
&w=3840&q=100)
Business Standard
11-07-2025
- Business
- Business Standard
Near-term upside from deal with AbbVie may be priced in Glenmark's stock
Glenmark's $700 million deal with AbbVie for ISB-2001 could unlock significant upside, though analysts note the potential is already priced in, with stock surging post-announcement premium Devangshu Datta Listen to This Article Glenmark Pharma (GNP) has just signed an exclusive licensing deal with AbbVie through its subsidiary, Ichnos Glenmark Innovation (IGI), for its lead investigational asset, ISB-2001. The deal could be transformative as it leverages IGI's BEAT protein platform for oncology and autoimmune diseases and the potential of ISB-2001 to treat relapsed and refractory multiple myelomas, underlining the commercial viability of ISB-2001 following successful clinical trials. AbbVie is considered a diversified biopharma leader. In oncology, it has built a robust presence anchored by cornerstone therapies, which have improved the treatment for chronic lymphocytic leukaemia and other B-cell malignancies, generating multi-billion-dollar
&w=3840&q=100)
Business Standard
11-07-2025
- Business Standard
Delhi Police directs Aerocity outlets to store CCTV footage for 90 days
The Delhi Police has directed all commercial establishments, including hotels and petrol pumps, in the Aerocity area to install "a sufficient number" of CCTV cameras covering a 50-metre radius in front of their premises, with mandatory storage of footage for at least 90 days. According to an order issued by ACP Vir Krishan Pal Singh (sub-division, Palam, IGI, airport), anyone contravening the order will be liable to be punished in accordance with the provisions of Section 223(a), which refers to disobedience of an order by a public servant, of the Bharatiya Nyaya Sanhita (BNS). The order, which comes ahead of Independence Day, will remain in force till September 2, officials said. "The owner/manager of the hotel/guest house/restaurant/petrol pump should ensure that the CCTV system is in proper working order and in case any defect is noticed, immediate action to get it rectified should be taken," according to the order issued last week. "An entry should be made in the register and intimation in writing should be sent to the police station simultaneously to be duly received from the duty officer of the police Station, mentioning the daily diary number on the intimation," it said. Aerocity, near the Indira Gandhi International Airport, is a hub of luxurious hotels, restaurants, and nightclubs. It sees a steady footfall of international tourists. Last month, three men impersonating police personnel allegedly robbed a motorcycle from a security guard in Aerocity. The order said, "There have been incidents of murder, rape, and robbery in the streets and hotels, guest houses, restaurants, petrol pumps, banquet halls for marriage and other functions in Delhi in the past, causing loss of life and property." Therefore, it is necessary to take speedy measures in this regard to prevent danger to human life or safety and to thwart any untoward incidents which may affect the peace and tranquillity of the area, it said. "The owner/manager of the hotel/guest house shall maintain a proper entry record of persons and copies of IDs who book a room for temporary or permanent stay. "During the course of monitoring of the CCTV system, the manager or anyone specifically designated by the owner/manager for real time monitoring of the CCTV shall immediately inform the Police Control Room on number 112 and also the nearest police station in case any suspect person or activity is noticed," the order said. Establishment owners are also required to hand over a copy of the footage whenever demanded by authorities, it said. The order, however, does not specify the exact number of CCTV cameras to be installed.
Business Standard
11-07-2025
- Business
- Business Standard
Glenmark Pharma soars on AbbVie licensing deal for cancer therapy ISB 2001
Glenmark Pharmaceuticals hit an upper limit of 10% to a record high of Rs 2095.65 after its subsidiary Ichnos Glenmark Innovation (IGI) unveiled a global commercialization strategy for its lead investigational oncology asset, ISB 2001. The announcement follows a major licensing agreement with U.S. biopharma giant AbbVie. Under the terms of the agreement, IGI will collaborate with AbbVie to develop, manufacture, and commercialize ISB 2001, a first-in-class trispecific T-cell engager designed to treat multiple myeloma. AbbVie will handle development and commercialization in North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals will take charge of manufacturing and marketing the therapy in Emerging Markets, including Asia (excluding key developed markets), Latin America, the Russia/CIS region, the Middle East, Africa, Australia, New Zealand, and South Korea. ISB 2001, currently in Phase 1 clinical development, targets BCMA and CD38 on myeloma cells and CD3 on T cells. Developed using IGI's proprietary BEAT protein platform, the asset is engineered to enhance efficacy even at low antigen expression levels while aiming to improve safety over traditional bispecific antibodies. Data presented at the 2025 ASCO Annual Meeting showed promising results: a 79% overall response rate and 30% complete/stringent complete response in a heavily pretreated patient population. The therapy has also received Orphan Drug Designation (July 2023) and Fast Track Designation (May 2025) from the U.S. FDA for relapsed/refractory multiple myeloma. With this landmark deal, Glenmark is poised to strengthen its footprint in the global oncology market while expanding patient access to next-gen immunotherapies across high-need regions. "Our collaboration with AbbVie and Glenmark reflects IGI's mission to accelerate access to transformative multispecifics for patients worldwide," said Cyril Konto, M.D., President, Executive Director and CEO of IGI. "AbbVie's reach in major markets combined with Glenmark's commercial strength in Emerging Markets, creates complementary access pathways for ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma." "At Glenmark, we are committed to expanding access to innovative cancer treatments across Emerging Markets where unmet need and growth potential intersect," said Christoph Stoller, President Europe and Emerging Markets, Glenmark Pharmaceuticals. "The addition of ISB 2001 is a natural evolution of our oncology strategy. With our deep commercial footprint, strong regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA and TEVIMBRA in India, and rights to commercialize QiNHAYO (envafolimab), a PD-L1 checkpoint inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for patients with difficult-to-treat cancers through ISB 2001." Headquartered in New York, IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Glenmark Pharmaceuticals is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.
